Patents by Inventor Con Panousis

Con Panousis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
    Publication number: 20240117073
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: April 26, 2023
    Publication date: April 11, 2024
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard C. Nice, Anne Murray, George Mark
  • CD131 binding proteins and uses thereof
    Patent number: 11840573
    Abstract: The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: December 12, 2023
    Assignee: CSL LIMITED
    Inventors: Catherine Owczarek, Con Panousis, Nicholas Wilson, Matthew Hardy, Kirsten Edwards, Veronika Rayzman
  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20230086472
    Abstract: A serum albumin variant, or functional fragment thereof, comprising, one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: August 30, 2022
    Publication date: March 23, 2023
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten Edwards, Con PANOUSIS
  • Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
    Patent number: 11505619
    Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 22, 2022
    Assignee: CSL Limited
    Inventors: Malgorzata Wygrecka, Marc Nolte, Con Panousis
  • Complement C2 Binding Proteins and Uses Thereof
    Publication number: 20220332804
    Abstract: The present disclosure relates to proteins comprising antigen binding sites that bind to human complement C2 (C2). The present disclosure also relates to methods of inhibiting complement activity in a subject as well as methods of treating or preventing complement-mediated disorders.
    Type: Application
    Filed: August 12, 2020
    Publication date: October 20, 2022
    Applicant: CSL Innovation Pty Ltd.
    Inventors: Matthew Hardy, Con Panousis, Rodrigo Morales
  • Human serum albumin variants and uses thereof
    Patent number: 11466073
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 11, 2022
    Assignee: CSL Limited
    Inventors: Sabine Rauth, Andrew Hammet, Kirsten Edwards, Con Panousis
  • METHOD OF INHIBITING OR ACTIVATING GAMMA DELTA T CELLS
    Publication number: 20220273713
    Abstract: The present disclosure relates to methods for inhibiting activation of ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
    Type: Application
    Filed: June 26, 2020
    Publication date: September 1, 2022
    Applicants: The University of Melbourne, Olivia Newton-John Cancer Research Institute, CSL INNOVATION PTY LTD
    Inventors: Andreas BEHREN, Jonathan CEBON, Marc Rigau CORTAL, Thomas Samuel FULFORD, Dale Ian GODFREY, Andrew HAMMET, Simone OSTROUSKA, Con PANOUSIS, Adam Peter ULDRICH
  • Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
    Publication number: 20220089778
    Abstract: A membrane targeted binding protein that binds to at least one blood coagulation factor, wherein the binding protein has pro-coagulant activity.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 24, 2022
    Inventors: Peter SCHMIDT, Chao-Guang CHEN, Con PANOUSIS, Louis FABRI
  • METHOD OF TREATING ATHEROSCLEROSIS
    Publication number: 20220017638
    Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.
    Type: Application
    Filed: October 11, 2021
    Publication date: January 20, 2022
    Inventors: Con PANOUSIS, Karlheinz PETER, Hamid HOSSEINI, Yung-Chih CHEN
  • Method of treating atherosclerosis
    Patent number: 11174321
    Abstract: The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 16, 2021
    Assignee: CSL LIMITED
    Inventors: Con Panousis, Karlheinz Peter, Hamid Hosseini, Yung-Chih Chen
  • METHOD OF TREATING CANCER
    Publication number: 20210292411
    Abstract: The present disclosure provides a method for enhancing or inducing an immune response and/or for inducing lysis of cancer cells and/or for treating cancer in a subject, the method comprising administering to the subject a compound that neutralizes BTN2A1 and/or that binds to BTN2A1 on the cells and induces death of the cells.
    Type: Application
    Filed: November 4, 2020
    Publication date: September 23, 2021
    Inventors: Andreas BEHREN, Jonathan CEBON, Christopher HUDSON, Katherine WOODS, Andrew HAMMET, Anne VERHAGEN, Eugene MARASKOVSKY, Con PANOUSIS
  • USE OF A FXIIA-INHIBITOR IN THE TREATMENT OF RENAL FIBROSIS AND/OR CHRONIC KIDNEY DISEASE
    Publication number: 20210070879
    Abstract: The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 11, 2021
    Inventors: Malgorzata WYGRECKA, Marc NOLTE, Con PANOUSIS
  • METHODS OF TREATING NEOPLASTIC ASTROCYTOMA
    Publication number: 20210032366
    Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 4, 2021
    Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew M. Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark
  • ANTIBODIES AGAINST G-CSFR AND USES THEREOF
    Publication number: 20210009701
    Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Applicant: CSL LIMITED
    Inventors: Andrew Donald Nash, Arna Elizabeth Andrews, Manuel Baca, Kirsten Mae Edwards, Matthew Philip Hardy, Con Panousis, Felicity Meredith Dunlop
  • Mutated von Willebrand factor
    Patent number: 10808023
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The modified polypeptide comprises a sequence as shown in SEQ ID NO:3 in which the sequence comprises at least one modification at a position selected from the group consisting of L18, V42, K149, N248, S279, V320, T325, Q395 and K418 such that the modified polypeptide binds to Factor VIII with an off rate lower than a reference polypeptide comprising an unmodified SEQ ID NO:3.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 20, 2020
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Arna Andrews, Con Panousis, Kerstin Emmrich, Michael Wilson, Steve Dower, Matthew Hardy, Dallas Hartman
  • Mutated truncated von Willebrand Factor
    Patent number: 10806774
    Abstract: The present invention provides a modified polypeptide which binds Factor VIII. The polypeptide comprises truncated von Willebrand Factor (VWF) which comprises a sequence as shown in SEQ ID NO:3 or a fragment thereof or a sequence 90% identical thereto, wherein the truncated VWF comprises at least one modification in comparison to SEQ ID NO: 3 in at least one position selected from the group consisting of SI, S3, LI 8, V42, S43, K149, N248, S279, V320, T325, Q395 and K418.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: October 20, 2020
    Assignee: CSL BEHRING LENGNAU AG
    Inventors: Arna Andrews, Con Panousis, Kerstin Emmrich, Michael Wilson, Steve Dower, Matthew Hardy, Dallas Hartman
  • HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
    Publication number: 20200325209
    Abstract: A serum albumin variant, or functional fragment thereof, comprising one or more amino acid substitutions selected from (i) glycine, isoleucine, lysine, methionine, phenylalanine, tryptophan, tyrosine, valine and leucine substituted for glutamine at position (522); (ii) valine substituted for alanine at position (552); and (iii) alanine, glutamic acid, histidine, serine, lysine and arginine substituted for glycine at position (572).
    Type: Application
    Filed: October 18, 2018
    Publication date: October 15, 2020
    Applicant: CSL Limited
    Inventors: Sabine RAUTH, Andrew HAMMET, Kirsten EDWARDS, Con PANOUSIS
  • METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES
    Publication number: 20200062863
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 5, 2019
    Publication date: February 27, 2020
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 10513560
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 24, 2019
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte